WHI Questionnaires

Extension Study 2010-2025 (n=93,567)

Questionnaire2010201120122013201420152016201720182019202020212022
YYYYYYYYYYYYY
YYYYYYYY#P
Collection begins January 1, 2022.
Y
YY^
MR
Y
Y
Y
Y
Y
Y
Y
LLS
Y
*Form 521 in WHI started 6/22/2015 with a one-time administration.
Y
Questionnaire2010201120122013201420152016201720182019202020212022
Legend
  • Y = All Participants
  • MR = Medical Record Cohort
  • LLS = Long Life Study
  • # = Collected from proxies throughout 2021, and from both participants and proxies from June through December 2021.
  • ^ = Collected from participants only through May 2021.
  • P = Collected from proxies only.

Extension Study 2005-2010 (n=115,407)

Questionnaire20052006200720082009
YYYYY
If an event that needed adjudication was found on the form 33, a 33D was collected.
HTHT
Y
HTHTHTHTHT
YYYYY
Y
*All participants who previously reported diagnosis of breast cancer
%
Legend
  • Y = All Participants
  • HT = Hormone Trial
  • % = Subset, see notes for details

Clinical Trials & Observational Study

QuestionnaireBaseline123456789Closeout
Y
HT
HTHTHTHTHTHTHTHTHTHT
CaDCaDCaDCaDCaDCaDCaDCaDCaDCaD
Y
*For E+P, when intervention stopped July 9, 2002.
For E-Alone, when intervention stopped in February 2004.
HT
*At CaD study close-out October 2004-March 2005.
CaD
Y
Y
Y
Collected every 6 months for HT ppts
YYYYYYYYYCT
If an event that needed adjudication was found on the form 33, a 33D was collected.
Y
CTCTCTCT
YCT
CTCT%/OSCT%CT%
*HT cohort aged 65 and over.
HT%HT%HT%HT%HT%
Y
*Initiated in 2002 and collected once from all CT and OS participants at next routine contact.
OS
Y
YCTYCTCT
YCTYCTCT
OS
*For E+P participants on study through July 8, 2002, when intervention was stopped; administration began in March 2003.
entered if ppt needed to modify their study medication dosage
*For all E-Alone participants; administered twice:
*Year 2: 30% cross sectional 33% rotating subsample starting in the year 2000, such that for year 3 and each subsequent year each DM participant received an FFQ at once every 3 years.
YDMDM%DM%/OSDM%DM%DM%DM%DM%DM%
YCTCTYCTCTCTCTCTCT
YHTHTHTHTHTHTHTHTHT
Administered as indicated and as needed to manage unexpected bleeding. Not required after July 9, 2002, when intervention was stopped.
*5% E+P participants with uterus
HTHT%HT%HT%
*Done only if endometrial aspiration could not be done or was refused.
*Optional for DM participants.
YHTHTHTHTHTHTHTHTHT
YHTHTHTHTHTHTHTHTHTHT
CTCTCTCT
*Collected for ppts enrolled at 3 clinical centers or about 6-7% of total WHI. Yr1 collection limited to CT
%%%%%
*Sample was selected from the HT and DM > 65 years old.
CT%CT%CT%CT%
Y
*6% CT subsample. Year 6 collection was plasma only
YYCT%/OSCT%/OSCT%
*% - Collected at 3 BMD clinical centers. Year 9 collection was for 25% of OS ppts
CT/OS%CT%CT/OS%CT%OS%
OS
OS
OS
OS
OS
OS
*For OS participants who did not reach Year 7 by Closeout
OS
QuestionnaireBaseline123456789Closeout
Legend
  • Y = All Participants
  • CT = All Clinical Trials
  • OS = Observation Studies
  • HT = Hormone Trial
  • CaD = Calcium/Vitamin D Trial
  • DM = Dietary Modification Trial
  • % = Subset, see notes for details